Biogen Inc. (BIIB) has a consensus analyst rating of Buy, based on 48 analysts covering the stock. Of those, 25 recommend buying, 22 recommend holding, and 1 recommend selling.
The analyst consensus price target for BIIB is $207.60, representing a +16.0% upside from the current price of $178.96. Price targets range from a low of $143.00 to a high of $250.00.
